Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMBTX-01 (Neridronate) Open-Label Extension for CRPS-1
NCT07857733Phase 3Recruiting
- Sponsor
- Ambros Therapeutics
- Start
- Oct 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
A Phase 3 trial of neridronic acid in Complex Regional Pain Syndrome Type 1 (CRPS-1), sponsored by Ambros Therapeutics. Started Oct 2026; status: recruiting.
02
Drugs
neridronic acid
03
Conditions
Complex Regional Pain Syndrome Type 1 (CRPS-1)
Beyond the preview
Go deeper on NCT07857733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07857733.